Deverra Therapeutics

Colleen Delaney, Founder and CSO, presented Deverra's assets and product pipeline this morning at the Cell & Gene Meeting on the Mesa in Phoenix, AZ. So excited to participate in this conference, and we're looking forward to meeting this week with other pioneers in the GCT space! #CGMesa24 #cellandgenetherapy #allogeneiccelltherapy #oncology #dilanubicel #AML #monocytes #NKcells

📣 Deverra Therapeutics is proud to be one of the companies selected for a company presentation at the upcoming Cell and Gene Meeting on the Mesa! Will you be there too? If so, come to our company presentation on Monday at 9:45am, Ballroom F and send us a note in the partnering system to meet. Our CSO and Founder Colleen Delaney and our VP of Discovery and Translational Research Erika von Euw, will be there and welcome the opportunity to meet with other industry pioneers and stakeholders in the CGT space. See you there!!! #CGMesa24 #cellandgenetherapy #allogeneiccelltherapy #AML #dilanubicel

We are thrilled to have presented at the Annual Cord Blood Connect meeting in Miami at the beginning of the month. Sponsored by the #CBA, this meeting is the only gathering dedicated to advancing the use of cord blood and birthing tissue to benefit patients and advance medicine! 🎉 It was an amazing experience to connect with some of the brightest minds in the field, exchange ideas, and explore new avenues for collaboration. We were inspired by the shared passion for innovation and the potential of cord blood to revolutionize healthcare. From groundbreaking discussions to exciting new friendships forged, this event was truly fantastic. A big thank you to everyone who made this year's Cord Blood Connect Meeting so special! See you again next year! Looking forward to the many partnerships and projects ahead! 🌟 #CBC2024 #CBC2025 #CordBloodSavesLives #CordBlood #CGT #Innovation

We are excited to welcome John Centanni as the newest member of the Deverra Therapeutics team!

Stem Cell Manufacturing Market Worth $21.8 billion by 2028 ✅𝐆𝐞𝐭 𝐔𝐥𝐭𝐢𝐦𝐚𝐭𝐞 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞-https://lnkd.in/e2vDGMXa The global stem cell manufacturing market in terms of revenue was estimated to be worth $12.7 billion in 2023 and is poised to reach $21.8 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US), Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), etc 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲 PT Prodia StemCell Indonesia Deverra Therapeutics      INNOVIA BIOBANK   Biogenuix Medsystems Pvt Ltd      HebeCell Corp PL BioScience GmbH Anja Health  Society for Brain Mapping & Therapeutics (SBMT)      Generate Life Sciences      Cynata Therapeutics Future Health Biobank    NextCell Pharma AB National Center for Cell Science Colorado Springs Orthopaedic Group      Medistra Hospital   Akari Therapeutics, Plc SSCB | Swiss Stem Cells Biotech | Bio-Banca Cellule Staminali      Qkine Bioceltix  Epistem Ltd. DKMS BMST Foundation India      Axent Biosciences    AIVITA Biomedical, Inc.  CellVoyant WiCell Bacterin International, Inc.      Nordic Biosite Biopelle MedCells Intl. FZ LLC    Lifeline Cell Technology Stempeutics Research Private Limited      Venkata Narayana Active Ingredients Pvt. Ltd.      Morphocell Technologies    XNK Therapeutics  Biological Industries Sartorius  Cordlife Group Limited   ORF Genetics

Did you know that July is #cordblood awareness month? At Deverra, umbilical cord blood is central to who we are and the cell therapies we are developing. It's even in our name! Read the story behind our name below. #cordbloodawareness #cordblooddonation #savetheCordBloodsavetheworld #celltherapy #allogeneic

Thanks to the organizers of the Allogeneic Cell Therapy Summit for inviting Colleen Delaney to participate. Dr. Delaney was on a panel discussing the ideal starting material for allogeneic cell therapies and presented a plenary talk on Deverra's pooled cord blood donor manufacturing that results in a scalable, consistent and cost-effective approach for the generation of cellular immunotherapies. Our lead asset, #dilanubicel, was just granted #RMAT, #FastTrack and #OrphanDrug designations for treatment of AML using this manufacturing approach. The future of #allogeneic cell therapies is bright!! 😎 Next up: come see presentations by Deverra Therapeutics at the annual #CordBloodConnect and #CARTCR summit in September! Stay tuned for more details! #cordblood #AML #celltherapy

How are new drugs developed??? It can be a very long process, but Deverra is well on its way with its lead cell therapy asset, dilanubicel. #celltherapy #allogeneic #AML

How are new drugs developed??? It can be a very long process, but Deverra is well on its way with its lead cell therapy asset, dilanubicel. #celltherapy #allogeneic #AML

We are excited to announce that Deverra will have multiple presentations at the upcoming ISCT, International Society for Cell & Gene Therapy meeting taking place May 29-June 1, 2024, in Vancouver, BC, Canada. These presentations will focus on Deverra's use of pooled donor manufacturing of dilanubicel to overcome the barriers associated with allogeneic cell therapy development (Abstract #810), Deverra's breakthroughs in generating therapeutically relevant quantities of highly functional allogeneic monocytes and macrophages from pooled donor umbilical cord blood stem cells (Abstract #989), and Deverra’s partnership with Coeptis Therapeutics in the development of an antigen agnostic universal donor SNAP-CAR natural killer cell therapy by integrating Coeptis’ SNAP-CAR technology with Deverra’s universal NK cell generation platform (Abstract #6). At Deverra, we remain committed to advancing the frontiers of next-generation cellular immunotherapies with the goal of making life-saving cell therapies accessible and affordable for everyone. We look forward to attending the conference to hear about all the great work happening in the cell and gene therapy field and to meet new people, make new connections and forge new collaborations. Come see us!! Details on the dates/times of the four presentations at the ISCT meeting are as follows: Poster Presentations: Wednesday, May 29, 2024 (7-8:30 PM) 🙌 Developing a First-In-Class Universal Allogeneic SNAP-CAR NK Cell Therapy 🙌 Overcoming Current Challenges in Allogeneic Cell Therapy Manufacturing by Using Pooled Donor Cord Blood CD34+ Cells as Starting Material 🙌 Generation of Monocytes and Macrophages from CD34+ Cord Blood Cells for Cell Therapy Oral Presentation: Thursday, May 30, 2024 (8:00 -9:00 AM) 🎉 Developing a First-In-Class Universal Allogeneic SNAP-CAR NK Cell Therapy #ISCT #Allogeneic #CellTherapy #Universal